Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7945258 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Determinants of tofacitinib discontinuation in adult patients with rheumatoid arthritis during long-term extension studies up to 9.5 years.
Rheumatol Adv Pract
May 2024
Pfizer Hellas A.E., Cyprus Branch, Strovolos, Cyprus.
Objectives: To examine determinants of tofacitinib discontinuation due to voluntary (i.e. patient-driven) or involuntary reasons (i.
View Article and Find Full Text PDFRapid and fully automated blood vasculature analysis in 3D light-sheet image volumes of different organs.
Cell Rep Methods
March 2023
Center for Protein Diagnostics (ProDi), Ruhr-University Bochum, Bochum, Germany.
Article Synopsis
- Light-sheet fluorescence microscopy (LSFM) is effective for high-resolution imaging of tissue vasculature but faces challenges with labor-intensive data processing due to large datasets.!* -
- VesselExpress is a new automated software that analyzes key vascular network parameters quickly and efficiently, being around 100 times faster than existing tools and requiring no user input.!* -
- The software uses a unique dual Frangi filter approach to reveal significant changes in brain vasculature due to obesity and highlights distinct 3D vascular differences across various organs.!*
Sensitivity and Specificity of Autoantibodies Against CD74 in Nonradiographic Axial Spondyloarthritis.
Arthritis Rheumatol
May 2019
Hannover Medical School, Hannover, Germany.
Objective: Autoantibodies against CD74 (anti-CD74) are associated with ankylosing spondylitis (AS). The present multicenter study, the International Spondyloarthritis Autoantibody (InterSpA) trial, was undertaken to compare the sensitivity and specificity of anti-CD74 and HLA-B27 in identifying patients with nonradiographic axial spondyloarthritis (axSpA).
Methods: Patients ages 18-45 years with inflammatory back pain of ≤2 years' duration and a clinical suspicion of axSpA were recruited.
Time of Disease-Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drug-Free Remission in Young Adulthood.
Arthritis Care Res (Hoboken)
April 2019
German Rheumatism Research Center and Charité-University Medicine Berlin, Berlin, Germany.
Objective: To study juvenile idiopathic arthritis (JIA) long-term outcomes in relation to the time of initiation of biologic disease-modifying antirheumatic drug (bDMARD).
Methods: Outcomes of JIA patients prospectively followed by the Biologika in der Kinderrheumatologie (BiKeR) and Juvenile Arthritis Methotrexate/Biologics Long-Term Observation (JuMBO) registers were analyzed with regard to drug-free remission and inactive disease, functional status and quality of life, and surgery. To analyze the influence of early bDMARD therapy on outcomes, patients were assigned to 3 groups based on the time from symptom onset to bDMARD start (G1: ≤2 years, G2: >2 to ≤5 years, and G3: >5 years).
[Fentanyl buccal tablets in the treatment of breakthrough cancer pain. German cohort of a pan-European multicentre study].
MMW Fortschr Med
July 2018
, Neustadt/Sachsen, Deutschland.
Background: Patients with breakthrough cancer pain (BtCP) experience significant limitations in their physical, mental and social functions. Fentanyl buccal tablets (FBT), a rapid onset opioid, are specifically indicated for the treatment of BtCP.
Method: The results of the German cohort of a pan-European study are presented.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!